SPECIFICITIES OF THE SUBSET PROFILE OF PERIPHERAL BLOOD IN PATIENTS WITH GLIOBLASTOMA: PATHOGENETIC AND CLINICAL ASSESSMENTS

Abstract. In glioblastoma (GB), it is necessary to take into consideration GB-associated secondary immunodeficiency (SID), so-called syndrome of tumor-associated SID (STASID). Cell subsets having effector and regulatory functions, play an important role in developing STASID, and their proportions in...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	V. A. Chumakov [verfasserIn] O. A. Pronina [verfasserIn] I. A. Kachkov [verfasserIn] A. G. Korshounov [verfasserIn] B. V. Pineguin [verfasserIn] I. I. Anan’eva [verfasserIn] T. Elbeik [verfasserIn] L. S. Metelitsa [verfasserIn] A. E. Dorofeev [verfasserIn] N. V. Gnouchev [verfasserIn] S. V. Souchkov [verfasserIn]

Format:	E-Artikel
Sprache:	Russisch

Erschienen:	2014

Schlagwörter:	glioblastoma secondary immunodeficiency autoimmune syndrome lympholytes subpopulations anti-tumor immunity

Übergeordnetes Werk:	In: Медицинская иммунология - St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists, 2015, 8(2014), 1, Seite 37-50
Übergeordnetes Werk:	volume:8 ; year:2014 ; number:1 ; pages:37-50

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.15789/1563-0625-2006-1-37-50

Katalog-ID:	DOAJ080799094

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ080799094
003	DE-627
005	20240413082204.0
007	cr uuu---uuuuu
008	230310s2014 xx \|\|\|\|\|o 00\| \|\|rus c
024	7		\|a 10.15789/1563-0625-2006-1-37-50 \|2 doi
035			\|a (DE-627)DOAJ080799094
035			\|a (DE-599)DOAJ0d85015c494a4ec09bab63f483d9478f
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a rus
050		0	\|a RC581-607
100	0		\|a V. A. Chumakov \|e verfasserin \|4 aut
245	1	0	\|a SPECIFICITIES OF THE SUBSET PROFILE OF PERIPHERAL BLOOD IN PATIENTS WITH GLIOBLASTOMA: PATHOGENETIC AND CLINICAL ASSESSMENTS
264		1	\|c 2014
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Abstract. In glioblastoma (GB), it is necessary to take into consideration GB-associated secondary immunodeficiency (SID), so-called syndrome of tumor-associated SID (STASID). Cell subsets having effector and regulatory functions, play an important role in developing STASID, and their proportions in patients with different forms of GB can be of pathogenetic importance and have clinical value for treatment and rehabilitation scheduling as well. The most pathogenically and clinically important features of cell subsets profile of peripheral blood were analyzed in patients with different clinical and morphological types of GB. The patients were divided into three groups, i.e., groups I and II were formed by patients with STASID (marked and slightly marked SID, accordingly); group III – patients with SIDTAS (tumor-associated autoimmune syndrome, associated with SID). Marked suppression of cell immunity is typical of group I - imbalance in T-lymphocytes, in a number of specific subsets, and in subsets clusters, as well as disproportions in the immunoregulatory indexes. In group II, the subset profiles of blood were slightly different from the norm. In patients with SIDTAS, activation of cell immunity was evident, forming SID with signs of autoimmune syndrome, affecting effector and regulatory chains of immunity, and influencing the severity and forecast of the disease. Specific features of the immune status in patients with GB identified can be resulted from different clinicalmorphological types of the tumor; the latter are to be considered in differential diagnostics of clinical course of GB and in scheduling of clinical-immunological efficient anti-tumor pharmacotherapy in pre- and postoperative periods.
650		4	\|a glioblastoma
650		4	\|a secondary immunodeficiency
650		4	\|a autoimmune syndrome
650		4	\|a lympholytes subpopulations
650		4	\|a anti-tumor immunity
653		0	\|a Immunologic diseases. Allergy
700	0		\|a O. A. Pronina \|e verfasserin \|4 aut
700	0		\|a I. A. Kachkov \|e verfasserin \|4 aut
700	0		\|a A. G. Korshounov \|e verfasserin \|4 aut
700	0		\|a B. V. Pineguin \|e verfasserin \|4 aut
700	0		\|a I. I. Anan’eva \|e verfasserin \|4 aut
700	0		\|a T. Elbeik \|e verfasserin \|4 aut
700	0		\|a L. S. Metelitsa \|e verfasserin \|4 aut
700	0		\|a A. E. Dorofeev \|e verfasserin \|4 aut
700	0		\|a N. V. Gnouchev \|e verfasserin \|4 aut
700	0		\|a S. V. Souchkov \|e verfasserin \|4 aut
773	0	8	\|i In \|t Медицинская иммунология \|d St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists, 2015 \|g 8(2014), 1, Seite 37-50 \|w (DE-627)1735558133 \|x 2313741X \|7 nnns
773	1	8	\|g volume:8 \|g year:2014 \|g number:1 \|g pages:37-50
856	4	0	\|u https://doi.org/10.15789/1563-0625-2006-1-37-50 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/0d85015c494a4ec09bab63f483d9478f \|z kostenfrei
856	4	0	\|u https://www.mimmun.ru/mimmun/article/view/424 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1563-0625 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2313-741X \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 8 \|j 2014 \|e 1 \|h 37-50

Indexfelder

author_variant	v a c vac o a p oap i a k iak a g k agk b v p bvp i i a iia t e te l s m lsm a e d aed n v g nvg s v s svs
matchkey_str	article:2313741X:2014----::pcfcteoteustrfloprpeabodnainsihlolsoaahg
hierarchy_sort_str	2014
callnumber-subject-code	RC
publishDate	2014
allfields	10.15789/1563-0625-2006-1-37-50 doi (DE-627)DOAJ080799094 (DE-599)DOAJ0d85015c494a4ec09bab63f483d9478f DE-627 ger DE-627 rakwb rus RC581-607 V. A. Chumakov verfasserin aut SPECIFICITIES OF THE SUBSET PROFILE OF PERIPHERAL BLOOD IN PATIENTS WITH GLIOBLASTOMA: PATHOGENETIC AND CLINICAL ASSESSMENTS 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract. In glioblastoma (GB), it is necessary to take into consideration GB-associated secondary immunodeficiency (SID), so-called syndrome of tumor-associated SID (STASID). Cell subsets having effector and regulatory functions, play an important role in developing STASID, and their proportions in patients with different forms of GB can be of pathogenetic importance and have clinical value for treatment and rehabilitation scheduling as well. The most pathogenically and clinically important features of cell subsets profile of peripheral blood were analyzed in patients with different clinical and morphological types of GB. The patients were divided into three groups, i.e., groups I and II were formed by patients with STASID (marked and slightly marked SID, accordingly); group III – patients with SIDTAS (tumor-associated autoimmune syndrome, associated with SID). Marked suppression of cell immunity is typical of group I - imbalance in T-lymphocytes, in a number of specific subsets, and in subsets clusters, as well as disproportions in the immunoregulatory indexes. In group II, the subset profiles of blood were slightly different from the norm. In patients with SIDTAS, activation of cell immunity was evident, forming SID with signs of autoimmune syndrome, affecting effector and regulatory chains of immunity, and influencing the severity and forecast of the disease. Specific features of the immune status in patients with GB identified can be resulted from different clinicalmorphological types of the tumor; the latter are to be considered in differential diagnostics of clinical course of GB and in scheduling of clinical-immunological efficient anti-tumor pharmacotherapy in pre- and postoperative periods. glioblastoma secondary immunodeficiency autoimmune syndrome lympholytes subpopulations anti-tumor immunity Immunologic diseases. Allergy O. A. Pronina verfasserin aut I. A. Kachkov verfasserin aut A. G. Korshounov verfasserin aut B. V. Pineguin verfasserin aut I. I. Anan’eva verfasserin aut T. Elbeik verfasserin aut L. S. Metelitsa verfasserin aut A. E. Dorofeev verfasserin aut N. V. Gnouchev verfasserin aut S. V. Souchkov verfasserin aut In Медицинская иммунология St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists, 2015 8(2014), 1, Seite 37-50 (DE-627)1735558133 2313741X nnns volume:8 year:2014 number:1 pages:37-50 https://doi.org/10.15789/1563-0625-2006-1-37-50 kostenfrei https://doaj.org/article/0d85015c494a4ec09bab63f483d9478f kostenfrei https://www.mimmun.ru/mimmun/article/view/424 kostenfrei https://doaj.org/toc/1563-0625 Journal toc kostenfrei https://doaj.org/toc/2313-741X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2014 1 37-50
spelling	10.15789/1563-0625-2006-1-37-50 doi (DE-627)DOAJ080799094 (DE-599)DOAJ0d85015c494a4ec09bab63f483d9478f DE-627 ger DE-627 rakwb rus RC581-607 V. A. Chumakov verfasserin aut SPECIFICITIES OF THE SUBSET PROFILE OF PERIPHERAL BLOOD IN PATIENTS WITH GLIOBLASTOMA: PATHOGENETIC AND CLINICAL ASSESSMENTS 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract. In glioblastoma (GB), it is necessary to take into consideration GB-associated secondary immunodeficiency (SID), so-called syndrome of tumor-associated SID (STASID). Cell subsets having effector and regulatory functions, play an important role in developing STASID, and their proportions in patients with different forms of GB can be of pathogenetic importance and have clinical value for treatment and rehabilitation scheduling as well. The most pathogenically and clinically important features of cell subsets profile of peripheral blood were analyzed in patients with different clinical and morphological types of GB. The patients were divided into three groups, i.e., groups I and II were formed by patients with STASID (marked and slightly marked SID, accordingly); group III – patients with SIDTAS (tumor-associated autoimmune syndrome, associated with SID). Marked suppression of cell immunity is typical of group I - imbalance in T-lymphocytes, in a number of specific subsets, and in subsets clusters, as well as disproportions in the immunoregulatory indexes. In group II, the subset profiles of blood were slightly different from the norm. In patients with SIDTAS, activation of cell immunity was evident, forming SID with signs of autoimmune syndrome, affecting effector and regulatory chains of immunity, and influencing the severity and forecast of the disease. Specific features of the immune status in patients with GB identified can be resulted from different clinicalmorphological types of the tumor; the latter are to be considered in differential diagnostics of clinical course of GB and in scheduling of clinical-immunological efficient anti-tumor pharmacotherapy in pre- and postoperative periods. glioblastoma secondary immunodeficiency autoimmune syndrome lympholytes subpopulations anti-tumor immunity Immunologic diseases. Allergy O. A. Pronina verfasserin aut I. A. Kachkov verfasserin aut A. G. Korshounov verfasserin aut B. V. Pineguin verfasserin aut I. I. Anan’eva verfasserin aut T. Elbeik verfasserin aut L. S. Metelitsa verfasserin aut A. E. Dorofeev verfasserin aut N. V. Gnouchev verfasserin aut S. V. Souchkov verfasserin aut In Медицинская иммунология St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists, 2015 8(2014), 1, Seite 37-50 (DE-627)1735558133 2313741X nnns volume:8 year:2014 number:1 pages:37-50 https://doi.org/10.15789/1563-0625-2006-1-37-50 kostenfrei https://doaj.org/article/0d85015c494a4ec09bab63f483d9478f kostenfrei https://www.mimmun.ru/mimmun/article/view/424 kostenfrei https://doaj.org/toc/1563-0625 Journal toc kostenfrei https://doaj.org/toc/2313-741X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2014 1 37-50
allfields_unstemmed	10.15789/1563-0625-2006-1-37-50 doi (DE-627)DOAJ080799094 (DE-599)DOAJ0d85015c494a4ec09bab63f483d9478f DE-627 ger DE-627 rakwb rus RC581-607 V. A. Chumakov verfasserin aut SPECIFICITIES OF THE SUBSET PROFILE OF PERIPHERAL BLOOD IN PATIENTS WITH GLIOBLASTOMA: PATHOGENETIC AND CLINICAL ASSESSMENTS 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract. In glioblastoma (GB), it is necessary to take into consideration GB-associated secondary immunodeficiency (SID), so-called syndrome of tumor-associated SID (STASID). Cell subsets having effector and regulatory functions, play an important role in developing STASID, and their proportions in patients with different forms of GB can be of pathogenetic importance and have clinical value for treatment and rehabilitation scheduling as well. The most pathogenically and clinically important features of cell subsets profile of peripheral blood were analyzed in patients with different clinical and morphological types of GB. The patients were divided into three groups, i.e., groups I and II were formed by patients with STASID (marked and slightly marked SID, accordingly); group III – patients with SIDTAS (tumor-associated autoimmune syndrome, associated with SID). Marked suppression of cell immunity is typical of group I - imbalance in T-lymphocytes, in a number of specific subsets, and in subsets clusters, as well as disproportions in the immunoregulatory indexes. In group II, the subset profiles of blood were slightly different from the norm. In patients with SIDTAS, activation of cell immunity was evident, forming SID with signs of autoimmune syndrome, affecting effector and regulatory chains of immunity, and influencing the severity and forecast of the disease. Specific features of the immune status in patients with GB identified can be resulted from different clinicalmorphological types of the tumor; the latter are to be considered in differential diagnostics of clinical course of GB and in scheduling of clinical-immunological efficient anti-tumor pharmacotherapy in pre- and postoperative periods. glioblastoma secondary immunodeficiency autoimmune syndrome lympholytes subpopulations anti-tumor immunity Immunologic diseases. Allergy O. A. Pronina verfasserin aut I. A. Kachkov verfasserin aut A. G. Korshounov verfasserin aut B. V. Pineguin verfasserin aut I. I. Anan’eva verfasserin aut T. Elbeik verfasserin aut L. S. Metelitsa verfasserin aut A. E. Dorofeev verfasserin aut N. V. Gnouchev verfasserin aut S. V. Souchkov verfasserin aut In Медицинская иммунология St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists, 2015 8(2014), 1, Seite 37-50 (DE-627)1735558133 2313741X nnns volume:8 year:2014 number:1 pages:37-50 https://doi.org/10.15789/1563-0625-2006-1-37-50 kostenfrei https://doaj.org/article/0d85015c494a4ec09bab63f483d9478f kostenfrei https://www.mimmun.ru/mimmun/article/view/424 kostenfrei https://doaj.org/toc/1563-0625 Journal toc kostenfrei https://doaj.org/toc/2313-741X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2014 1 37-50
allfieldsGer	10.15789/1563-0625-2006-1-37-50 doi (DE-627)DOAJ080799094 (DE-599)DOAJ0d85015c494a4ec09bab63f483d9478f DE-627 ger DE-627 rakwb rus RC581-607 V. A. Chumakov verfasserin aut SPECIFICITIES OF THE SUBSET PROFILE OF PERIPHERAL BLOOD IN PATIENTS WITH GLIOBLASTOMA: PATHOGENETIC AND CLINICAL ASSESSMENTS 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract. In glioblastoma (GB), it is necessary to take into consideration GB-associated secondary immunodeficiency (SID), so-called syndrome of tumor-associated SID (STASID). Cell subsets having effector and regulatory functions, play an important role in developing STASID, and their proportions in patients with different forms of GB can be of pathogenetic importance and have clinical value for treatment and rehabilitation scheduling as well. The most pathogenically and clinically important features of cell subsets profile of peripheral blood were analyzed in patients with different clinical and morphological types of GB. The patients were divided into three groups, i.e., groups I and II were formed by patients with STASID (marked and slightly marked SID, accordingly); group III – patients with SIDTAS (tumor-associated autoimmune syndrome, associated with SID). Marked suppression of cell immunity is typical of group I - imbalance in T-lymphocytes, in a number of specific subsets, and in subsets clusters, as well as disproportions in the immunoregulatory indexes. In group II, the subset profiles of blood were slightly different from the norm. In patients with SIDTAS, activation of cell immunity was evident, forming SID with signs of autoimmune syndrome, affecting effector and regulatory chains of immunity, and influencing the severity and forecast of the disease. Specific features of the immune status in patients with GB identified can be resulted from different clinicalmorphological types of the tumor; the latter are to be considered in differential diagnostics of clinical course of GB and in scheduling of clinical-immunological efficient anti-tumor pharmacotherapy in pre- and postoperative periods. glioblastoma secondary immunodeficiency autoimmune syndrome lympholytes subpopulations anti-tumor immunity Immunologic diseases. Allergy O. A. Pronina verfasserin aut I. A. Kachkov verfasserin aut A. G. Korshounov verfasserin aut B. V. Pineguin verfasserin aut I. I. Anan’eva verfasserin aut T. Elbeik verfasserin aut L. S. Metelitsa verfasserin aut A. E. Dorofeev verfasserin aut N. V. Gnouchev verfasserin aut S. V. Souchkov verfasserin aut In Медицинская иммунология St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists, 2015 8(2014), 1, Seite 37-50 (DE-627)1735558133 2313741X nnns volume:8 year:2014 number:1 pages:37-50 https://doi.org/10.15789/1563-0625-2006-1-37-50 kostenfrei https://doaj.org/article/0d85015c494a4ec09bab63f483d9478f kostenfrei https://www.mimmun.ru/mimmun/article/view/424 kostenfrei https://doaj.org/toc/1563-0625 Journal toc kostenfrei https://doaj.org/toc/2313-741X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2014 1 37-50
allfieldsSound	10.15789/1563-0625-2006-1-37-50 doi (DE-627)DOAJ080799094 (DE-599)DOAJ0d85015c494a4ec09bab63f483d9478f DE-627 ger DE-627 rakwb rus RC581-607 V. A. Chumakov verfasserin aut SPECIFICITIES OF THE SUBSET PROFILE OF PERIPHERAL BLOOD IN PATIENTS WITH GLIOBLASTOMA: PATHOGENETIC AND CLINICAL ASSESSMENTS 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract. In glioblastoma (GB), it is necessary to take into consideration GB-associated secondary immunodeficiency (SID), so-called syndrome of tumor-associated SID (STASID). Cell subsets having effector and regulatory functions, play an important role in developing STASID, and their proportions in patients with different forms of GB can be of pathogenetic importance and have clinical value for treatment and rehabilitation scheduling as well. The most pathogenically and clinically important features of cell subsets profile of peripheral blood were analyzed in patients with different clinical and morphological types of GB. The patients were divided into three groups, i.e., groups I and II were formed by patients with STASID (marked and slightly marked SID, accordingly); group III – patients with SIDTAS (tumor-associated autoimmune syndrome, associated with SID). Marked suppression of cell immunity is typical of group I - imbalance in T-lymphocytes, in a number of specific subsets, and in subsets clusters, as well as disproportions in the immunoregulatory indexes. In group II, the subset profiles of blood were slightly different from the norm. In patients with SIDTAS, activation of cell immunity was evident, forming SID with signs of autoimmune syndrome, affecting effector and regulatory chains of immunity, and influencing the severity and forecast of the disease. Specific features of the immune status in patients with GB identified can be resulted from different clinicalmorphological types of the tumor; the latter are to be considered in differential diagnostics of clinical course of GB and in scheduling of clinical-immunological efficient anti-tumor pharmacotherapy in pre- and postoperative periods. glioblastoma secondary immunodeficiency autoimmune syndrome lympholytes subpopulations anti-tumor immunity Immunologic diseases. Allergy O. A. Pronina verfasserin aut I. A. Kachkov verfasserin aut A. G. Korshounov verfasserin aut B. V. Pineguin verfasserin aut I. I. Anan’eva verfasserin aut T. Elbeik verfasserin aut L. S. Metelitsa verfasserin aut A. E. Dorofeev verfasserin aut N. V. Gnouchev verfasserin aut S. V. Souchkov verfasserin aut In Медицинская иммунология St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists, 2015 8(2014), 1, Seite 37-50 (DE-627)1735558133 2313741X nnns volume:8 year:2014 number:1 pages:37-50 https://doi.org/10.15789/1563-0625-2006-1-37-50 kostenfrei https://doaj.org/article/0d85015c494a4ec09bab63f483d9478f kostenfrei https://www.mimmun.ru/mimmun/article/view/424 kostenfrei https://doaj.org/toc/1563-0625 Journal toc kostenfrei https://doaj.org/toc/2313-741X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2014 1 37-50
language	Russian
source	In Медицинская иммунология 8(2014), 1, Seite 37-50 volume:8 year:2014 number:1 pages:37-50
sourceStr	In Медицинская иммунология 8(2014), 1, Seite 37-50 volume:8 year:2014 number:1 pages:37-50
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	glioblastoma secondary immunodeficiency autoimmune syndrome lympholytes subpopulations anti-tumor immunity Immunologic diseases. Allergy
isfreeaccess_bool	true
container_title	Медицинская иммунология
authorswithroles_txt_mv	V. A. Chumakov @@aut@@ O. A. Pronina @@aut@@ I. A. Kachkov @@aut@@ A. G. Korshounov @@aut@@ B. V. Pineguin @@aut@@ I. I. Anan’eva @@aut@@ T. Elbeik @@aut@@ L. S. Metelitsa @@aut@@ A. E. Dorofeev @@aut@@ N. V. Gnouchev @@aut@@ S. V. Souchkov @@aut@@
publishDateDaySort_date	2014-01-01T00:00:00Z
hierarchy_top_id	1735558133
id	DOAJ080799094
language_de	russisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ080799094</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413082204.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230310s2014 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.15789/1563-0625-2006-1-37-50</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ080799094</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ0d85015c494a4ec09bab63f483d9478f</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC581-607</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">V. A. Chumakov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">SPECIFICITIES OF THE SUBSET PROFILE OF PERIPHERAL BLOOD IN PATIENTS WITH GLIOBLASTOMA: PATHOGENETIC AND CLINICAL ASSESSMENTS</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract. In glioblastoma (GB), it is necessary to take into consideration GB-associated secondary immunodeficiency (SID), so-called syndrome of tumor-associated SID (STASID). Cell subsets having effector and regulatory functions, play an important role in developing STASID, and their proportions in patients with different forms of GB can be of pathogenetic importance and have clinical value for treatment and rehabilitation scheduling as well. The most pathogenically and clinically important features of cell subsets profile of peripheral blood were analyzed in patients with different clinical and morphological types of GB. The patients were divided into three groups, i.e., groups I and II were formed by patients with STASID (marked and slightly marked SID, accordingly); group III – patients with SIDTAS (tumor-associated autoimmune syndrome, associated with SID). Marked suppression of cell immunity is typical of group I - imbalance in T-lymphocytes, in a number of specific subsets, and in subsets clusters, as well as disproportions in the immunoregulatory indexes. In group II, the subset profiles of blood were slightly different from the norm. In patients with SIDTAS, activation of cell immunity was evident, forming SID with signs of autoimmune syndrome, affecting effector and regulatory chains of immunity, and influencing the severity and forecast of the disease. Specific features of the immune status in patients with GB identified can be resulted from different clinicalmorphological types of the tumor; the latter are to be considered in differential diagnostics of clinical course of GB and in scheduling of clinical-immunological efficient anti-tumor pharmacotherapy in pre- and postoperative periods.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">glioblastoma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">secondary immunodeficiency</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">autoimmune syndrome</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lympholytes subpopulations</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">anti-tumor immunity</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Immunologic diseases. Allergy</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">O. A. Pronina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I. A. Kachkov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. G. Korshounov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">B. V. Pineguin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I. I. Anan’eva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">T. Elbeik</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">L. S. Metelitsa</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. E. Dorofeev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">N. V. Gnouchev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S. V. Souchkov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Медицинская иммунология</subfield><subfield code="d">St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists, 2015</subfield><subfield code="g">8(2014), 1, Seite 37-50</subfield><subfield code="w">(DE-627)1735558133</subfield><subfield code="x">2313741X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:37-50</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.15789/1563-0625-2006-1-37-50</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/0d85015c494a4ec09bab63f483d9478f</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mimmun.ru/mimmun/article/view/424</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1563-0625</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2313-741X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2014</subfield><subfield code="e">1</subfield><subfield code="h">37-50</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	V. A. Chumakov
spellingShingle	V. A. Chumakov misc RC581-607 misc glioblastoma misc secondary immunodeficiency misc autoimmune syndrome misc lympholytes subpopulations misc anti-tumor immunity misc Immunologic diseases. Allergy SPECIFICITIES OF THE SUBSET PROFILE OF PERIPHERAL BLOOD IN PATIENTS WITH GLIOBLASTOMA: PATHOGENETIC AND CLINICAL ASSESSMENTS
authorStr	V. A. Chumakov
ppnlink_with_tag_str_mv	@@773@@(DE-627)1735558133
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC581-607
illustrated	Not Illustrated
issn	2313741X
topic_title	RC581-607 SPECIFICITIES OF THE SUBSET PROFILE OF PERIPHERAL BLOOD IN PATIENTS WITH GLIOBLASTOMA: PATHOGENETIC AND CLINICAL ASSESSMENTS glioblastoma secondary immunodeficiency autoimmune syndrome lympholytes subpopulations anti-tumor immunity
topic	misc RC581-607 misc glioblastoma misc secondary immunodeficiency misc autoimmune syndrome misc lympholytes subpopulations misc anti-tumor immunity misc Immunologic diseases. Allergy
topic_unstemmed	misc RC581-607 misc glioblastoma misc secondary immunodeficiency misc autoimmune syndrome misc lympholytes subpopulations misc anti-tumor immunity misc Immunologic diseases. Allergy
topic_browse	misc RC581-607 misc glioblastoma misc secondary immunodeficiency misc autoimmune syndrome misc lympholytes subpopulations misc anti-tumor immunity misc Immunologic diseases. Allergy
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Медицинская иммунология
hierarchy_parent_id	1735558133
hierarchy_top_title	Медицинская иммунология
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1735558133
title	SPECIFICITIES OF THE SUBSET PROFILE OF PERIPHERAL BLOOD IN PATIENTS WITH GLIOBLASTOMA: PATHOGENETIC AND CLINICAL ASSESSMENTS
ctrlnum	(DE-627)DOAJ080799094 (DE-599)DOAJ0d85015c494a4ec09bab63f483d9478f
title_full	SPECIFICITIES OF THE SUBSET PROFILE OF PERIPHERAL BLOOD IN PATIENTS WITH GLIOBLASTOMA: PATHOGENETIC AND CLINICAL ASSESSMENTS
author_sort	V. A. Chumakov
journal	Медицинская иммунология
journalStr	Медицинская иммунология
callnumber-first-code	R
lang_code	rus
isOA_bool	true
recordtype	marc
publishDateSort	2014
contenttype_str_mv	txt
container_start_page	37
author_browse	V. A. Chumakov O. A. Pronina I. A. Kachkov A. G. Korshounov B. V. Pineguin I. I. Anan’eva T. Elbeik L. S. Metelitsa A. E. Dorofeev N. V. Gnouchev S. V. Souchkov
container_volume	8
class	RC581-607
format_se	Elektronische Aufsätze
author-letter	V. A. Chumakov
doi_str_mv	10.15789/1563-0625-2006-1-37-50
author2-role	verfasserin
title_sort	specificities of the subset profile of peripheral blood in patients with glioblastoma: pathogenetic and clinical assessments
callnumber	RC581-607
title_auth	SPECIFICITIES OF THE SUBSET PROFILE OF PERIPHERAL BLOOD IN PATIENTS WITH GLIOBLASTOMA: PATHOGENETIC AND CLINICAL ASSESSMENTS
abstract	Abstract. In glioblastoma (GB), it is necessary to take into consideration GB-associated secondary immunodeficiency (SID), so-called syndrome of tumor-associated SID (STASID). Cell subsets having effector and regulatory functions, play an important role in developing STASID, and their proportions in patients with different forms of GB can be of pathogenetic importance and have clinical value for treatment and rehabilitation scheduling as well. The most pathogenically and clinically important features of cell subsets profile of peripheral blood were analyzed in patients with different clinical and morphological types of GB. The patients were divided into three groups, i.e., groups I and II were formed by patients with STASID (marked and slightly marked SID, accordingly); group III – patients with SIDTAS (tumor-associated autoimmune syndrome, associated with SID). Marked suppression of cell immunity is typical of group I - imbalance in T-lymphocytes, in a number of specific subsets, and in subsets clusters, as well as disproportions in the immunoregulatory indexes. In group II, the subset profiles of blood were slightly different from the norm. In patients with SIDTAS, activation of cell immunity was evident, forming SID with signs of autoimmune syndrome, affecting effector and regulatory chains of immunity, and influencing the severity and forecast of the disease. Specific features of the immune status in patients with GB identified can be resulted from different clinicalmorphological types of the tumor; the latter are to be considered in differential diagnostics of clinical course of GB and in scheduling of clinical-immunological efficient anti-tumor pharmacotherapy in pre- and postoperative periods.
abstractGer	Abstract. In glioblastoma (GB), it is necessary to take into consideration GB-associated secondary immunodeficiency (SID), so-called syndrome of tumor-associated SID (STASID). Cell subsets having effector and regulatory functions, play an important role in developing STASID, and their proportions in patients with different forms of GB can be of pathogenetic importance and have clinical value for treatment and rehabilitation scheduling as well. The most pathogenically and clinically important features of cell subsets profile of peripheral blood were analyzed in patients with different clinical and morphological types of GB. The patients were divided into three groups, i.e., groups I and II were formed by patients with STASID (marked and slightly marked SID, accordingly); group III – patients with SIDTAS (tumor-associated autoimmune syndrome, associated with SID). Marked suppression of cell immunity is typical of group I - imbalance in T-lymphocytes, in a number of specific subsets, and in subsets clusters, as well as disproportions in the immunoregulatory indexes. In group II, the subset profiles of blood were slightly different from the norm. In patients with SIDTAS, activation of cell immunity was evident, forming SID with signs of autoimmune syndrome, affecting effector and regulatory chains of immunity, and influencing the severity and forecast of the disease. Specific features of the immune status in patients with GB identified can be resulted from different clinicalmorphological types of the tumor; the latter are to be considered in differential diagnostics of clinical course of GB and in scheduling of clinical-immunological efficient anti-tumor pharmacotherapy in pre- and postoperative periods.
abstract_unstemmed	Abstract. In glioblastoma (GB), it is necessary to take into consideration GB-associated secondary immunodeficiency (SID), so-called syndrome of tumor-associated SID (STASID). Cell subsets having effector and regulatory functions, play an important role in developing STASID, and their proportions in patients with different forms of GB can be of pathogenetic importance and have clinical value for treatment and rehabilitation scheduling as well. The most pathogenically and clinically important features of cell subsets profile of peripheral blood were analyzed in patients with different clinical and morphological types of GB. The patients were divided into three groups, i.e., groups I and II were formed by patients with STASID (marked and slightly marked SID, accordingly); group III – patients with SIDTAS (tumor-associated autoimmune syndrome, associated with SID). Marked suppression of cell immunity is typical of group I - imbalance in T-lymphocytes, in a number of specific subsets, and in subsets clusters, as well as disproportions in the immunoregulatory indexes. In group II, the subset profiles of blood were slightly different from the norm. In patients with SIDTAS, activation of cell immunity was evident, forming SID with signs of autoimmune syndrome, affecting effector and regulatory chains of immunity, and influencing the severity and forecast of the disease. Specific features of the immune status in patients with GB identified can be resulted from different clinicalmorphological types of the tumor; the latter are to be considered in differential diagnostics of clinical course of GB and in scheduling of clinical-immunological efficient anti-tumor pharmacotherapy in pre- and postoperative periods.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1
title_short	SPECIFICITIES OF THE SUBSET PROFILE OF PERIPHERAL BLOOD IN PATIENTS WITH GLIOBLASTOMA: PATHOGENETIC AND CLINICAL ASSESSMENTS
url	https://doi.org/10.15789/1563-0625-2006-1-37-50 https://doaj.org/article/0d85015c494a4ec09bab63f483d9478f https://www.mimmun.ru/mimmun/article/view/424 https://doaj.org/toc/1563-0625 https://doaj.org/toc/2313-741X
remote_bool	true
author2	O. A. Pronina I. A. Kachkov A. G. Korshounov B. V. Pineguin I. I. Anan’eva T. Elbeik L. S. Metelitsa A. E. Dorofeev N. V. Gnouchev S. V. Souchkov
author2Str	O. A. Pronina I. A. Kachkov A. G. Korshounov B. V. Pineguin I. I. Anan’eva T. Elbeik L. S. Metelitsa A. E. Dorofeev N. V. Gnouchev S. V. Souchkov
ppnlink	1735558133
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.15789/1563-0625-2006-1-37-50
callnumber-a	RC581-607
up_date	2024-07-03T16:37:16.780Z
_version_	1803576553543565313
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ080799094</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413082204.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230310s2014 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.15789/1563-0625-2006-1-37-50</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ080799094</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ0d85015c494a4ec09bab63f483d9478f</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC581-607</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">V. A. Chumakov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">SPECIFICITIES OF THE SUBSET PROFILE OF PERIPHERAL BLOOD IN PATIENTS WITH GLIOBLASTOMA: PATHOGENETIC AND CLINICAL ASSESSMENTS</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract. In glioblastoma (GB), it is necessary to take into consideration GB-associated secondary immunodeficiency (SID), so-called syndrome of tumor-associated SID (STASID). Cell subsets having effector and regulatory functions, play an important role in developing STASID, and their proportions in patients with different forms of GB can be of pathogenetic importance and have clinical value for treatment and rehabilitation scheduling as well. The most pathogenically and clinically important features of cell subsets profile of peripheral blood were analyzed in patients with different clinical and morphological types of GB. The patients were divided into three groups, i.e., groups I and II were formed by patients with STASID (marked and slightly marked SID, accordingly); group III – patients with SIDTAS (tumor-associated autoimmune syndrome, associated with SID). Marked suppression of cell immunity is typical of group I - imbalance in T-lymphocytes, in a number of specific subsets, and in subsets clusters, as well as disproportions in the immunoregulatory indexes. In group II, the subset profiles of blood were slightly different from the norm. In patients with SIDTAS, activation of cell immunity was evident, forming SID with signs of autoimmune syndrome, affecting effector and regulatory chains of immunity, and influencing the severity and forecast of the disease. Specific features of the immune status in patients with GB identified can be resulted from different clinicalmorphological types of the tumor; the latter are to be considered in differential diagnostics of clinical course of GB and in scheduling of clinical-immunological efficient anti-tumor pharmacotherapy in pre- and postoperative periods.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">glioblastoma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">secondary immunodeficiency</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">autoimmune syndrome</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lympholytes subpopulations</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">anti-tumor immunity</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Immunologic diseases. Allergy</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">O. A. Pronina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I. A. Kachkov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. G. Korshounov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">B. V. Pineguin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I. I. Anan’eva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">T. Elbeik</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">L. S. Metelitsa</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. E. Dorofeev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">N. V. Gnouchev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S. V. Souchkov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Медицинская иммунология</subfield><subfield code="d">St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists, 2015</subfield><subfield code="g">8(2014), 1, Seite 37-50</subfield><subfield code="w">(DE-627)1735558133</subfield><subfield code="x">2313741X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:37-50</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.15789/1563-0625-2006-1-37-50</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/0d85015c494a4ec09bab63f483d9478f</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mimmun.ru/mimmun/article/view/424</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1563-0625</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2313-741X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2014</subfield><subfield code="e">1</subfield><subfield code="h">37-50</subfield></datafield></record></collection>
score	7.400549

Nicht das Richtige dabei?

Schreiben Sie uns!

SPECIFICITIES OF THE SUBSET PROFILE OF PERIPHERAL BLOOD IN PATIENTS WITH GLIOBLASTOMA: PATHOGENETIC AND CLINICAL ASSESSMENTS

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?